



Designation: **F813–07 (Reapproved 2012) F813 – 20**

Standard Practice for Direct Contact Cell Culture Evaluation of Materials for Medical Devices¹

This standard is issued under the fixed designation F813; the number immediately following the designation indicates the year of original adoption or, in the case of revision, the year of last revision. A number in parentheses indicates the year of last reapproval. A superscript epsilon (ϵ) indicates an editorial change since the last revision or reapproval.

1. Scope

1.1 This practice covers a reference method of direct contact cell culture testing which may be used in evaluating the cytotoxic potential of materials for use in the construction of medical materials and devices.

1.2 This practice may be used either directly to evaluate materials or as a reference against which other cytotoxicity test methods may be compared.

1.3 This is one of a series of reference test methods for the assessment of cytotoxic potential, employing different techniques.

1.4 Assessment of cytotoxicity is one of several tests employed in determining the biological response to a material, as recommended in Practice **F748**.

1.5 The L-929 cell line was chosen because it has a significant history of use in assays of this type. This is not intended to imply that its use is preferred; only that the L-929 is a ~~well-characterized~~, well characterized, readily available, established cell line that has demonstrated reproducible results in several laboratories.

~~1.6 Since the test sample is not removed at the time of microscopic evaluation and underlying cells may be affected by the specific gravity of the test sample, this practice is limited to evaluation of cells outside the perimeter of the overlying test sample.~~

1.6 The values stated in SI units are to be regarded as standard. No other units of measurement are included in this standard.

1.7 *This standard does not purport to address all of the safety concerns, if any, associated with its use. It is the responsibility of the user of this standard to establish appropriate ~~safety~~ safety, health, and health environmental practices and determine the applicability of regulatory limitations prior to use.*

1.8 *This international standard was developed in accordance with internationally recognized principles on standardization established in the Decision on Principles for the Development of International Standards, Guides and Recommendations issued by the World Trade Organization Technical Barriers to Trade (TBT) Committee.*

2. Referenced Documents

2.1 ASTM Standards:²

~~F619 Practice for Extraction of Medical Plastics~~

F748 Practice for Selecting Generic Biological Test Methods for Materials and Devices

F895 Test Method for Agar Diffusion Cell Culture Screening for Cytotoxicity

F1027 Practice for Assessment of Tissue and Cell Compatibility of Orofacial Prosthetic Materials and Devices

2.2 Other Documents:

The American Type Culture Collection (ATCC), Catalogue of Strains II³

USP Negative Control Plastic Reference Standard⁴

¹ This practice is under the jurisdiction of ASTM Committee **F04** on Medical and Surgical Materials and Devices and is the direct responsibility of Subcommittee **F04.16** on Biocompatibility Test Methods.

Current edition approved ~~Oct. 1, 2012~~ April 1, 2020. Published ~~November 2012~~ June 2020. Originally approved in 2001. Last previous edition approved in ~~2007~~ 2012 as **F813–07:F813–07(2012)**. DOI: ~~10.1520/F0813-07R12~~ 10.1520/F0813-20.

² For referenced ASTM standards, visit the ASTM website, www.astm.org, or contact ASTM Customer Service at service@astm.org. For *Annual Book of ASTM Standards* volume information, refer to the standard's Document Summary page on the ASTM website.

³ American Type Culture Collection, P.O. Box 1549, Manassas, VA 20108..

⁴ *U.S. Pharmacopeia*, Vol 24, Rand McNally, Taunton, MA, 1994, pp. 1652–1653. Use latest publication to ensure current cumulative revisions are used.

3. Summary of Practice

3.1 Cell cultures are grown to a confluent monolayer in culture dishes. The growth medium is aspirated and replenished to provide a resting, confluent cell layer. Test and control specimens are placed in direct contact with the cell layer to provide an accelerated assessment of the presence or absence of a cytotoxic effect from a given material or device. See Practice **F1027** for definitions.

4. Significance and Use

4.1 This practice is useful for assessing cytotoxic potential both when evaluating new materials or formulations for possible use in medical applications, and as part of a quality control program for established medical materials and medical devices.

4.2 This practice assumes that assessment of cytotoxicity potential provides one method for predicting the potential for cytotoxic or necrotic reactions to medical materials and devices during clinical applications to humans. In general, cell culture testing methods have shown good correlation with animal assays ~~and are frequently more sensitive to toxic moieties when only chemical toxicities are being considered.~~

NOTE 1—The results obtained using this method may not predict *in vivo* behavior which can be influenced by multiple factors such as those arising from site of application or physical properties that may result from design and fabrication.

4.3 This cell culture test method is suitable for adoption in specifications and standards for materials for use in the construction of medical devices that are intended to ~~be implanted in the human body or placed in~~ have direct contact with tissue, tissue fluids, or blood on a long-term basis. ~~blood.~~ However, care should be taken when testing materials that are ~~resorbable to be sure absorbable, include an eluting or degradable coating, are liquid or gelatinous in nature, are irregularly shaped solid materials, or have a high density or mass, to make sure that the method is applicable. If leachables from the test sample are capable of diffusing through the agar layer, agarose-based methods such as Test Method F895 may be considered as an alternate method, depending on sample characteristics, or in cases where investigators wish to further evaluate the cytotoxic response of cells underlying the test sample.~~

4.4 Since cells in this direct contact test method are not protected by an overlying agarose layer, they are more susceptible to potential mechanical damage imparted by the overlying test sample. Investigators wishing to evaluate the cytotoxic response of cells underlying the test sample should consider agarose-based methods similar to Test Method **F895**. Alternatively, depending on sample characteristics, extraction methods such as Practice **F619** may also be considered.

5. Apparatus

5.1 The following apparatus shall be used:

5.2 *Incubator*, to maintain a temperature of $37 \pm 2^\circ\text{C}$ ~~and 1°C with a humidified atmosphere of 4 to 6 % CO₂ with greater than 90 % relative humidity in air.~~

5.3 *Tissue Culture Grade Culture Dishes*, that are sterile and 3560 mm in diameter by 10 mm deep. Alternative sizes may be suitable if the grading recommended in Table 1 can be performed adequately.

NOTE 2—Plastic dishes are recommended because they provide a flat surface that contributes to the formation of a uniform cell monolayer.

5.4 *Disposable, Sterile, Centrifuge Tubes*.

5.5 *Inverted Optical Microscope*, with magnifications of 40×, 100×, and 200×.

5.6 *Clinical Centrifuge*, capable of attaining 1300xg.

5.7 *Filter Disks*—10 mm in diameter (for evaluation of liquids).

NOTE 3—Millipore AP2501000 filter disks have been found satisfactory for use in cytotoxicity evaluations because they elicit no cytopathic effect. Other filter disks that do not elicit a cytopathic effect may also be used.

5.8 *Water Bath*, capable of maintaining a temperature of $37 \pm 2^\circ\text{C}$.

NOTE 4—A laminar flow work area capable of filtering out 99.99 % of all particles greater than 0.5 μm in diameter, or a class 100 clean room may be necessary to prevent contamination of cultures.

6. Reagents

6.1 The following reagents shall be used:

6.1.1 *Minimum Essential Medium (MEM)*, prepared ~~without~~ with L-glutamine and augmented by the addition of Earle's salts and ~~5–10 %~~ 5–10 % fetal bovine serum.

NOTE 5—Glutamine ~~is~~ may be omitted from this formulation in order to maximize the shelf life of the medium. ~~Immediately before~~ Prior to use, 5 mL of L-glutamine solution (see 6.1.2) ~~are~~ should be added to each 500 mL of MEM.

NOTE 6—Opened containers of MEM may be stored at a temperature of 2 to 8°C for periods of not more than one week.

NOTE 7—Antibiotics, such as penicillin G10,000 I.U./ml and streptomycin 10,000 I.U./ml, may be added to the medium (1 ml of antibiotic per 100 ml of media) to reduce the incidence of bacterial contamination. This may, however, have an adverse effect on the viability of the cell cultures.

- 6.1.2 *L-glutamine Solution*, 29.2 mg/mL of sterile water.
- 6.1.3 *Hanks' Solution*, calcium-and magnesium-free (store at room temperature).
- 6.1.4 *Trypsin*, 0.1 % solution in Hanks' solution or calcium- and magnesium-free, phosphate-buffered saline (store frozen).
- 6.1.5 *Water*, distilled, deionized, and sterile, with a minimum resistivity of 1 MΩ·cm.
- 6.2 All reagents shall be tissue-culture grade or equivalent.
- 6.3 Reagents shall be reconstituted in accordance with the manufacturer's directions, using aseptic technique.
- 6.4 Reagents shall be stored in accordance with the manufacturer's directions unless otherwise indicated in 6.1.

7. Cell Cultures

7.1 Cell cultures used in this assay should be the ATCC, CCL 1 NCTC clone 929 strain (clone of Strain L, mouse connective tissue) designated L-929. Other suitable validated cell lines may be considered. Cells should be tested periodically for Mycoplasma contamination. A passage or doubling limit should be established within the laboratory with supportive data to prevent the use of aged cells in this practice, which may exhibit phenotypic abnormalities that could affect morphologic assessment.

8. Control Materials

8.1 Prepare negative control specimens in accordance with Section 10 from a material that consistently elicits negligible cellular response in this assay (for example, USP Negative Control Plastic Reference Standard).

8.2 Prepare positive control specimens in accordance with Section 10 from a material that consistently elicits a predictable, moderate degree of cytotoxicity.

8.2.1 Use aqueous phenol (0.45 ± 0.05 % by volume) as a positive control for a diffuse reaction of cellular degeneration and sloughing. Take care to ensure that the preparation is homogenous.

8.2.2 Latex rubber has been used as a positive polymeric control for a zone of ~~inhibition~~reactivity.

9. General Technique

9.1 Use the ~~aseptic~~ technique throughout this assay to minimize microbial contamination.

NOTE 8—Mouth pipetting should not be employed to transfer cells, medium, or reagents.

9.2 Warm all solutions and materials to a temperature of $37 \pm 2^\circ\text{C}$ before placing in contact with cells.

10. Preparation of Specimens

10.1 Sterilize all specimens by a method appropriate to the end use of the device.

10.2 Where a device is sufficiently small (see 10.3 and 10.4) to fit into the culture dish leaving an adequate margin of cells for evaluation, use the entire device as a specimen.

10.3 Cut large solid materials and devices in cross section to obtain a flat surface having an area of 100 to 250 mm² to be placed in direct contact with the cell monolayer.

10.4 Uneven items and tubing or rod-shaped materials and devices may be cut into cross sections and placed side to side to provide a flat test surface that covers an area of 100 mm² on the cell monolayer.

10.5 Prepare specimens of rod or Materials or devices with irregular or complex surface areas such as resins, non-soluble powders, pellets, or molding with porous or complex shapes may be placed on the cell monolayer so that it covers an area of 100 mm² tubing or of rod- or tube-shaped devices as follows: on the cell monolayer as uniformly as possible.

10.4.1 Where the diameter is less than 6.4 mm, cut 5 to 15 mm in length.

10.4.2 Where the diameter is 6.4 to 15 mm, cut 2 to 8 mm in length.

10.4.3 Where the diameter exceeds 15 mm, prepare cross-sections as described in 10.3.

10.6 Obtain specimens from larger medical items from locations with relatively large cross sections in order to expose interior material.

10.7 If a device is constructed of two or more materials, cut either the test specimen from the materials' interface or test separate specimens from each material.

10.8 Prepare specimens for evaluating the cytotoxicity of ~~liquids or extracts~~liquids, including negative and positive controls, by saturating a sterile filter disk (see 5.7) and allowing the excess liquid to drain off while maintaining asepsis. Use the saturated filter disk as a test specimen.

NOTE 9—When ethylene oxide or other chemical sterilants are used, adequate aeration time should be allowed, to permit dissipation of residues which may adversely affect the results recorded in this assay. The aeration time should be based on the time established by the sterilization validation procedure for the dissipation of the residues.

NOTE 10—In general, the specimens should be cleaned to remove any residues from specimen preparation, and sterilized after they have been cut to size—prepared following aseptic technique. If the large solid materials are very hard, like ~~ceramics~~hard (like ceramics) which require cutting with metal